Literature DB >> 6577218

Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens.

P G Natali, M Viora, M R Nicotra, P Giacomini, A Bigotti, S Ferrone.   

Abstract

Surgically removed benign and malignant human skin lesions of nonmelanocyte origin have been tested with monoclonal antibodies to la antigens, to the HLA-A,B antigenic molecular complex, and to melanoma-associated antigen(s) (MAA). MAA include a high-molecular-weight (HMW) MAA, a 115,000-molecular-weight MAA, a 94,000-molecular-weight MAA, and a cytoplasmic MAA. Indirect immunofluorescence was used as the assay system because of the limited amount of tissue available. When the amount of tissue available was sufficient, double determinant immunoassays (DDIA) were used to quantitate the level of the HMW MAA and of the cytoplasmic MAA. The results of the DDIA were in agreement with those of indirect immunofluorescence in more than 75% of the cases. Malignant skin tumors of various histiotypes displayed three types of changes: 1) appearance of la antigens and cytoplasmic MAA, 2) increase in the level of the HMW MAA, of a 115,000- and a 100,000-molecular-weight MAA, and 3) reduction in the level of HLA-A,B antigens and beta 2-microglobulin. A significant heterogeneity was found in the antigenic profile among various lesions of a given histiotype as well as among tumor cells within a given lesion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6577218

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  12 in total

Review 1.  Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system.

Authors:  Pooja Yesantharao; Wei Wang; Nilah M Ioannidis; Shadmehr Demehri; Alice S Whittemore; Maryam M Asgari
Journal:  Hum Immunol       Date:  2017-02-07       Impact factor: 2.850

2.  Interferon-mediated enhancement of metastasis. Are MHC antigens involved?

Authors:  P L Lollini; C De Giovanni; B Del Re; G Nicoletti; G Prodi; P Nanni
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

3.  Expression of HLA ABC and DR antigens in thyroid neoplasia and correlation with mononuclear leukocyte infiltration.

Authors:  M E Fisfalen; W A Franklin; L J DeGroot; R S Cajulis; K Soltani; M Ryan; N Jones
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

Review 4.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.

Authors:  G Parmiani; G Fossati; D Taramelli; A Anichini; A Balsari; C Gambacorti-Passerini; G Sciorelli; N Cascinelli
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

6.  Recombinant gamma interferon induces HLA-DR expression on squamous cell carcinoma, trichilemmoma, adenocarcinoma cell lines, and cultured human keratinocytes.

Authors:  K Kameyama; T Tone; H Eto; S Takezaki; T Kanzaki; S Nishiyama
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

7.  Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones.

Authors:  A Anichini; G Fossati; G Parmiani
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

8.  HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas.

Authors:  H F van den Ingh; D J Ruiter; G Griffioen; G N van Muijen; S Ferrone
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

Review 9.  Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.

Authors:  J Doukas; A Rolland
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

10.  A reassessment of the role of B7-1 expression in tumor rejection.

Authors:  T C Wu; A Y Huang; E M Jaffee; H I Levitsky; D M Pardoll
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.